You can buy or sell AKCA and other stocks, options, ETFs, and crypto commission-free!
Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. Read More It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Advertising and Marketing
Seeking AlphaMay 9
Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript
Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael MacLean - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Chad Messer - Needham Do Kim - BMO Capital Markets Subbu Nambi - Cowen Operator Good afternoon and welcome to your Akcea Therapeutics Fir...
Yahoo FinanceMay 8
Akcea Therapeutics Q1 Earnings and Revenues Lag Estimates
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 1
Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?
Akcea Therapeutics (AKCA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
$0.98 per share
$0.67 per share